Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy By Ogkologos - August 25, 2025 449 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a meta-analysis performed by the Early Breast Cancer Trialists’ Collaborative Group Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Reducing Health Care Disparities Through Cancer Clinical Trials November 30, 2020 Qué debe saber sobre las pruebas de ADN en el hogar... February 8, 2023 FDA Approves Lenvatinib Plus Pembrolizumab for Advanced Renal Cell Carcinoma August 12, 2021 Rationale Explained for Granting EMA Authorisation for Extended Use of Nivolumab... November 18, 2020 Load more HOT NEWS Trial Results Support SBRT as a Standard Option for Some Prostate... News digest – naked mole-rats, junk food deals, ovarian cancer drug... Corgi Named Dolly Didn’t Win At Westminster, But Is A Champion... Dog Finds Woman’s Lost Wedding Ring At The Beach
